Jonathan Violin, Viridian CEO

Pos­i­tive read­out? Pub­lic of­fer­ing: Virid­i­an plans to raise $175M on eye dis­ease ther­a­py da­ta

A year and a half af­ter re­brand­ing, Virid­i­an Ther­a­peu­tics ap­pears to have found a path for­ward.

On Mon­day, the Waltham, MA-based biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.